CLINICAL_TRIALS ClinicalTrials.gov record update

Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05054257
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:00.538165+00:00
Published At: 2025-01-06T00:00:00+00:00
Record Updated At: 2025-01-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia", "Non-Hodgkin\u0027s Lymphoma Refractory", "Non-Hodgkin\u0027s Lymphoma, Relapsed"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-01-06"
protocolSection.identificationModule.nctId: "NCT05054257"
protocolSection.identificationModule.officialTitle: "Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin\u0027s Lymphoma. a Dose Escalation, Open-label, Phase I Study."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.